Optimising Locally Delivered Drugs

11th June 2009

Novartis Institutes for Biomedical Research, Horsham, UK



Optimising Locally Delivered Drugs

Programme:

The delivery of drugs direct to the site of action offers the potential for exquisite efficacy and minimal side effects. Ready access to the target tissue is a pre-requisite for local delivery and many drugs have been developed to take advantage of local tissue access targeting e.g. skin, nasal tissue, tracheal tissue, the GI tract and the eye.

The particular complexities associated with local delivery will be discussed at this meeting including the design requirements for both novel drug substances and their formulation. This will be illustrated with several recent drug discovery case studies.

- 09.00 Registration and coffee
- 09.50 Introduction Novartis Representative
- 10.00 **Session 1 Chair: Mark Searcey,** *University of East Anglia* Retinal drug delivery: current options and future possibilities **Susan Barker**, *School of Chemical Sciences and Pharmacy, University of East Anglia*
- 10.45 The Dynamic Gastric Model A significant step closer to the real thing

 Martin Wickham, Institute for Food Research, Norwich
- 11.30 The Discovery and Development of Ezetrol™: Serendipity and Design in the Discovery of Ezetimibe **Duane Burnett**, Schering-Plough, USA
- 12.15 Getting compounds into wounds and scars: challenges to the drug discoverer

Rob Webster, Pfizer Global R&D, Sandwich

Register on-line at: www.smr.org.uk

PLEASE NOTE: All attendees must send us by email a passport-style photograph in advance. In addition, you should bring to the meeting a form of photo identification such as a passport, ID card or photo driving licence. These are required by Novartis to make admission to their site as smooth as possible.



Optimising Locally Delivered Drugs

Programme:

4	$\overline{}$	^	_				
-1	3		ш			n	n
_		u	···		u		ш

- 14.00 Session 2 Chair: Ruth Lock, Novartis
 Discovery of novel inhaled ENaC blockers
 Nichola Smith, Global Discovery Chemistry, Novartis
 Institutes for Biomedical Research, Horsham
- 14.45 A DMPK perspective of inhaled drug discovery from particle deposition and dissolution to absorption kinetics and PD effects

 Stephan Eirefelt, Astra-Zeneca, Sweden
- 15.30 Tea

Session 3 - Chair: Steve Collingwood, Novartis

- 15.55 Inhaled Adenosine A2a Agonists for COPD Simon Mantell, Pfizer Global R&D, Sandwich
- 16.40 Optimisation of a novel structural class of potent and selective PDE4 inhibitors for inhaled administration **Mike Woodrow**, *ImmunoEpigentic DPU Chemistry*, *GlaxoSmithKline R&D*
- 17.25 Close

SMR Meetings in 2009

Toxicities Encountered in Drug Discovery

24th September 2009 NHLI, London

SMR Award Meeting

10th December 2009 NHLI, London

Drugs

Name:	(Incl. Title)									
Address:	(Incl. Company Name)									
Tel:	Fax:									
Email:										
Dietary Requ	uirements: Vegetarian: Other:									
Registrat	ion Fees: (Novartis Discount Code):									
SMR membe Students:* *Students should	ers: £80 Non-Members: £120 Honorary Life Member £35 Retired members: £35 (FREE) attach a letter confirming their student status from their HoD/Supervisor to this booking form.									
Payment	t Methods:									
Cheque:	If you wish to pay by cheque, then please send your cheque made payable to Society for Medicines Research , together with this form to the address given below.									
Credit/Deb Card:	simply enter your card details below.									
Please note that deductions will be shown on your	Card Nr: Expiry Date: Cardholders address if different from above:									
statement with the reference 'associaction enterprises Itd'										
	esses of delegates will be included in a list given to all attendees. If you do NOT want your lease tick this box.									
•	re not refundable unless a cancellation is received at least 5 working days prior to the event.									
Delegate substitut	es are permitted at any time.									

Join on-line at www.smr.org.uk or through our secretariat at the address given below.

DATA PROTECTION ACT: By completing and returning this form you agree to allow the Society for Medicines Research to hold and process data about your registration on computer and to pass this information on to 3rd parties as may be required in order to provide the services being offered. The Society for Medicines Research does not rent or sell this data to other companies or organisations.